Illumina supports Norway's pioneering precision medicine study

By The Science Advisory Board staff writers

December 13, 2021 -- Illumina announced that it is supporting a precision medicine study in Norway to assess the efficacy of blood-based comprehensive genomic profiling (CGP) in cancer therapy selection testing.

The study will evaluate the cost-effectiveness of implementing blood-based CGP in the public healthcare system. The study, titled "IMPRESS-Norway," is designed to match previously approved cancer medicines with other tumors, depending on their molecular profile, to drive a precision medicine approach to cancer therapy selection. The CGP analysis will be done using Illumina's dynamic read analysis for genomics software.

Less-invasive CGP testing of blood samples could potentially replace tissue sampling, substantially increasing the number of patients who are able to have their tumors profiled and who can then be included in clinical trials for cancer therapy selection, according to the firm.

For the study, the CGP testing of blood and tissue samples will be carried out across a network of pathology departments that span Norwegian hospitals.

Rebus Bio acquires EEL Transcriptomics
Rebus Bio, an Illumina Ventures-backed company, announced that it has acquired the intellectual property and related assay assets of EEL Transcriptomics,...
Illumina for Startups pushes boundaries of genomics by supporting early-stage companies
Most scientists are familiar with the genomics giant Illumina, which is known for its DNA sequencing technologies. However, Illumina has an accelerator...
Illumina Ventures raises $325M to fund health startups
Illumina Ventures has raised $325 million for its second investment fund, which will support healthcare startups.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter